Navigation Links
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Date:2/6/2008

al vectors, lentiviral vectors appear to sustain expression of the delivered genes of interest for a longer period of time. Their safety profiles are currently being evaluated in clinical trials.

"These results are everything we've been hoping for," said Dr. Riku Rautsola, CEO and President of VIRxSYS. "VRX496 is a remarkably promising treatment for HIV. We are very excited about what we are seeing so far in our trials and are confident that these results will continue into Phase III."

The VIRxSYS results were presented at CROI on Tuesday, February 5th from 1-4 PM at session 124 in Hall A. The VIRxSYS poster was number 753.

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which has advanced to Phase 2 human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

Contact: Paul Gibney

Phone: (212) 255-5340

E-mail: pgibney@corinthgroup.com


'/>"/>
SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. Xenon Announces Appointment of VP, Discovery Research
7. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
10. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
11. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
... denounces life-destructive research in light of ... new discovery, ... have made a significant breakthrough in stem cell research,using adult skin cells ... Scientists from the University of Wisconsin at Madison announced that,they have identified ...
... to shine spotlight on crisis affecting 246 million ... people ... Day, leaders in the U.S. House of Representatives passed House,Concurrent Resolution 211 ... on November 14. Then, the next day, on,World Diabetes Day itself, the ...
Cached Biology Technology:Stem Cell Breakthrough Could End Human Embryonic Experimentation 2Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress 2
(Date:4/17/2014)... word for chili peppers. Information about archaeological remains of ... of the appearance of words for chili peppers in ... domesticated and highlight the value of multi-proxy data analysis. ... of nine papers presented in a special feature issue ... Sciences on plant and animal domestication edited by ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... revolutionize biomedical research, scientists have discovered a way to keep ... individual cancer patient alive in the laboratory which previously ... lab after dividing only a few times, and many common ... This new technique, described today online in the American ...
... activities has polluted lakes throughout the Northern Hemisphere for more ... evident even in remote lakes located thousands of miles from ... published in the journal Science Dec. 16, are ... deposits in 36 lakes using an approach similar to aquatic ...
... insects, high risk of attack has led to the ... in the larval stage. One caterpillar may look like ... Though crypsis may have its advantages, University of Florida ... caterpillars using another strategy previously best-known in adult butterflies: ...
Cached Biology News:Georgetown researchers lead discovery expected to significantly change biomedical research 2Nitrogen from humans pollutes remote lakes for more than a century 2Nitrogen from humans pollutes remote lakes for more than a century 3Caterpillars mimic one another for survival 2Caterpillars mimic one another for survival 3
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
Request Info...
...
Complete cell culture media with cytokines...
Biology Products: